Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 3
2006 3
2007 1
2008 6
2009 2
2010 5
2011 6
2012 4
2013 9
2014 16
2015 10
2016 10
2017 16
2018 22
2019 22
2020 24
2021 30
2022 36
2023 36
2024 28
2025 19
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

272 results

Results by year

Filters applied: . Clear all
Page 1
Remibrutinib in Chronic Spontaneous Urticaria.
Metz M, Giménez-Arnau A, Hide M, Lebwohl M, Mosnaim G, Saini S, Sussman G, Szalewski R, Haemmerle S, Lheritier K, Martzloff ED, Seko N, Wang P, Zharkov A, Maurer M; REMIX-1 and REMIX-2 Investigators; REMIX-1 Investigators; REMIX-2 Investigators. Metz M, et al. N Engl J Med. 2025 Mar 6;392(10):984-994. doi: 10.1056/NEJMoa2408792. N Engl J Med. 2025. PMID: 40043237 Clinical Trial.
Severe cutaneous adverse reactions.
Hung SI, Mockenhaupt M, Blumenthal KG, Abe R, Ueta M, Ingen-Housz-Oro S, Phillips EJ, Chung WH. Hung SI, et al. Among authors: chung wh. Nat Rev Dis Primers. 2024 Apr 25;10(1):30. doi: 10.1038/s41572-024-00514-0. Nat Rev Dis Primers. 2024. PMID: 38664435 Review.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
An updated review of the immunological mechanisms of keloid scars.
Lee CC, Tsai CH, Chen CH, Yeh YC, Chung WH, Chen CB. Lee CC, et al. Among authors: chung wh. Front Immunol. 2023 Mar 22;14:1117630. doi: 10.3389/fimmu.2023.1117630. eCollection 2023. Front Immunol. 2023. PMID: 37033989 Free PMC article. Review.
Recent progress in Stevens-Johnson syndrome/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment.
Hama N, Aoki S, Chen CB, Hasegawa A, Ogawa Y, Vocanson M, Asada H, Chu CY, Lan CE, Dodiuk-Gad RP, Fujiyama T, Hsieh TS, Ito K, Jerschow E, Mizukawa Y, Nakajima S, Nakamura K, Nicolas JF, Satoh TK, Shiohara T, Takahashi H, Tohyama M, Ueda T, Ura K, Watanabe H, Yamaguchi Y, Nordmann TM, Chung WH, Naisbitt D, Pincelli C, Pichler WJ, French LE, Phillips E, Abe R. Hama N, et al. Among authors: chung wh. Br J Dermatol. 2024 Dec 23;192(1):9-18. doi: 10.1093/bjd/ljae321. Br J Dermatol. 2024. PMID: 39141587 Review.
Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions.
Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, Chang CJ, Su SC, Hui RC, Chin SW, Huang LF, Lin YY, Chang WY, Fan WL, Yang CY, Ho JC, Chang YC, Lu CW, Chung WH; the Taiwan Severe Cutaneous Adverse Reaction (TSCAR) Consortium. Wang CW, et al. Among authors: chung wh. J Clin Invest. 2018 Mar 1;128(3):985-996. doi: 10.1172/JCI93349. Epub 2018 Feb 5. J Clin Invest. 2018. PMID: 29400697 Free PMC article. Clinical Trial.
Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade.
Chen CB, Hung SI, Chang JW, Yang CK, Ma DH, Teng YC, Lu CW, Chen WT, Yang HY, Tsai CC, Wang CL, Chiang PH, Wu J, Tsai YW, Lu LY, Lin YY, Hui RC, Hsieh FM, Hsu CK, Lee CN, Chen YJ, Chen CC, Cui Y, Hsu HC, Chang YC, Chang CJ, Lin HC, Chang CJ, Lin YJ, Ku CL, Wang CW, Chung WH. Chen CB, et al. Among authors: chung wh. Nat Commun. 2024 Dec 30;15(1):10733. doi: 10.1038/s41467-024-54180-7. Nat Commun. 2024. PMID: 39737932 Free PMC article.
Treatment Outcomes of Immune-Related Cutaneous Adverse Events.
Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, Chan D, Dusza S, Motzer RJ, Rosenberg JE, Callahan MK, Chapman PB, Geskin L, Lopez AT, Reed VA, Fabbrocini G, Annunziata MC, Kukoyi O, Pabani A, Yang CH, Chung WH, Markova A, Lacouture ME. Phillips GS, et al. Among authors: chung wh. J Clin Oncol. 2019 Oct 20;37(30):2746-2758. doi: 10.1200/JCO.18.02141. Epub 2019 Jun 19. J Clin Oncol. 2019. PMID: 31216228 Free PMC article.
272 results